about
90Y-edotreotide for metastatic carcinoid refractory to octreotide.Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases.Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues.Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.Safety, Biodistribution, and Radiation Dosimetry of (68)Ga-OPS202 ((68)Ga-NODAGA-JR11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.Comparison of 68Ga-OPS202 (68Ga-NODAGA-JR11) and 68Ga-DOTATOC (68Ga-Edotreotide) PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Evaluation of Sensitivity in a Prospective Phase II Imaging Study.Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect.
P50
Q34101554-AF27615A-DE48-44C5-ABA3-D991C8BD4F1FQ34546925-22852209-3948-4008-9F0F-7EFD6BB92C87Q35987499-DED1526A-5C4A-4794-9523-EB78665A00E1Q44312549-FF2C2005-C604-4291-B5B6-1C7990308150Q44592499-37386CA9-89E0-4540-979B-37D96A6C6103Q44919924-DF467FB8-FC90-453B-B2CC-5C9345F87E7CQ44976964-4E728708-67F9-41C5-82B7-729C20A2D997Q46141324-0FA271BF-F9BC-4C35-9646-55AA3959706CQ46578935-38A7D273-C4EB-46FC-ACEC-0FB5C3630984Q46975692-3D28B98F-47EE-4A9E-86E0-1A3D59A30175Q47388629-05D4E00E-B774-43B4-8555-F4C58F63BC1CQ50694723-7F047156-A911-42CB-8844-37AD0720AEFD
P50
description
onderzoeker
@nl
name
Hakim Bouterfa
@ast
Hakim Bouterfa
@en
Hakim Bouterfa
@es
Hakim Bouterfa
@nl
Hakim Bouterfa
@sl
type
label
Hakim Bouterfa
@ast
Hakim Bouterfa
@en
Hakim Bouterfa
@es
Hakim Bouterfa
@nl
Hakim Bouterfa
@sl
prefLabel
Hakim Bouterfa
@ast
Hakim Bouterfa
@en
Hakim Bouterfa
@es
Hakim Bouterfa
@nl
Hakim Bouterfa
@sl
P106
P21
P31
P569
2000-01-01T00:00:00Z